219 related articles for article (PubMed ID: 9469362)
21. [Treatment of metastatic testicular carcinoma according to prognosis; new development].
de Wit R; Stoter G
Ned Tijdschr Geneeskd; 2001 Jun; 145(25):1194-9. PubMed ID: 11447874
[TBL] [Abstract][Full Text] [Related]
22. Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation.
Leyvraz S; Perey L; Rosti G; Lange A; Pampallona S; Peters R; Humblet Y; Bosquée L; Pasini F; Marangolo M
J Clin Oncol; 1999 Nov; 17(11):3531-9. PubMed ID: 10550151
[TBL] [Abstract][Full Text] [Related]
23. Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20).
Fosså SD; de Wit R; Roberts JT; Wilkinson PM; de Mulder PH; Mead GM; Cook P; de Prijck L; Stenning S; Aaronson NK; Bottomley A; Collette L; ;
J Clin Oncol; 2003 Mar; 21(6):1107-18. PubMed ID: 12637478
[TBL] [Abstract][Full Text] [Related]
24. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors.
Christian JA; Huddart RA; Norman A; Mason M; Fossa S; Aass N; Nicholl EJ; Dearnaley DP; Horwich A
J Clin Oncol; 2003 Mar; 21(5):871-7. PubMed ID: 12610187
[TBL] [Abstract][Full Text] [Related]
25. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study.
Dimopoulos MA; Papadimitriou C; Hamilos G; Efstathiou E; Vlahos G; Rodolakis A; Aravantinos G; Kalofonos H; Kouroussis C; Gika D; Skarlos D; Bamias A
Gynecol Oncol; 2004 Dec; 95(3):695-700. PubMed ID: 15581984
[TBL] [Abstract][Full Text] [Related]
26. Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial.
Bajorin DF; Nichols CR; Schmoll HJ; Kantoff PW; Bokemeyer C; Demetri GD; Einhorn LH; Bosl GJ
J Clin Oncol; 1995 Jan; 13(1):79-86. PubMed ID: 7799046
[TBL] [Abstract][Full Text] [Related]
27. Sequential intermediate high-dose therapy with etoposide, ifosfamide and cisplatin for patients with germ cell tumors.
Mardiak J; Fuchsberger P; Lakota J; Sálek T; Sycová-Milá Z; Drahokoupilová M; Baláz M; Koza I
Neoplasma; 2000; 47(4):239-43. PubMed ID: 11043829
[TBL] [Abstract][Full Text] [Related]
28. r-metHuG-CSF support to ifosfamide, cisplatin, etoposide chemotherapy in non-small cell lung cancer.
Gautier V; Pujol JL; Zinaï A; Michel FB
Lung Cancer; 1996 Jun; 14(2-3):343-51. PubMed ID: 8794415
[TBL] [Abstract][Full Text] [Related]
29. A phase II trial of VP-16, ifosfamide, cisplatin, vinblastine, and bleomycin in advanced germ-cell tumors.
Blanke C; Loehrer PJ; Nichols CR; Einhorn LH
Am J Clin Oncol; 1996 Oct; 19(5):487-91. PubMed ID: 8823477
[TBL] [Abstract][Full Text] [Related]
30. Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC). Medical Research Council Lung Cancer Working Party.
Thatcher N; Clark PI; Smith DB; Anderson H; Girling DJ; Machin D; Stephens RJ; Lallemand G; Jenkins B
Clin Oncol (R Coll Radiol); 1995; 7(5):293-9. PubMed ID: 8580054
[TBL] [Abstract][Full Text] [Related]
31. Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor Therapy.
Fridrik MA; Greil R; Hausmaninger H; Krieger O; Oppitz P; Stöger M; Klocker J; Neubauer M; Helm W; Pont J; Fazeny B; Hudec M; Simonitsch I; Radaszkiewicz T
Ann Hematol; 1997 Oct; 75(4):135-40. PubMed ID: 9402845
[TBL] [Abstract][Full Text] [Related]
32. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors.
Bokemeyer C; Köhrmann O; Tischler J; Weissbach L; Räth U; Haupt A; Schöffski P; Harstrick A; Schmoll HJ
Ann Oncol; 1996 Dec; 7(10):1015-21. PubMed ID: 9037359
[TBL] [Abstract][Full Text] [Related]
33. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
Bokemeyer C; Harstrick A; Beyer J; Metzner B; Rüther U; Hartmann JT; Holstein K; Derigs HG; de Wit R; Casper J; Schöffski P; Kührer I; Illiger HJ; Kempf B; Reichle A; Föller A; Hossfeld DK; Fischer JT; Berdel WE; Gerhartz HH; Kirchner H; Pflüger KH; Ostermann H; Kanz L; Schmoll HJ
Semin Oncol; 1998 Apr; 25(2 Suppl 4):24-32; discussion 45-8. PubMed ID: 9578059
[TBL] [Abstract][Full Text] [Related]
34. [Colony stimulating factors in polychemotherapy of testicular tumors. A comparison between G-CSF and GM-CSF].
Will R; Hofmockel G; Langer W; Frohmüller H
Urologe A; 1999 May; 38(3):258-63. PubMed ID: 10407985
[TBL] [Abstract][Full Text] [Related]
35. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.
Vose JM; Crump M; Lazarus H; Emmanouilides C; Schenkein D; Moore J; Frankel S; Flinn I; Lovelace W; Hackett J; Liang BC
J Clin Oncol; 2003 Feb; 21(3):514-9. PubMed ID: 12560443
[TBL] [Abstract][Full Text] [Related]
36. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
Furuse K; Fukuoka M; Nishiwaki Y; Kurita Y; Watanabe K; Noda K; Ariyoshi Y; Tamura T; Saijo N
J Clin Oncol; 1998 Jun; 16(6):2126-32. PubMed ID: 9626212
[TBL] [Abstract][Full Text] [Related]
37. Accelerated chemotherapy for poor prognosis germ cell tumours.
Horwich A; Dearnaley DP; Norman A; Nicolls J; Hendry WF
Eur J Cancer; 1994; 30A(11):1607-11. PubMed ID: 7530470
[TBL] [Abstract][Full Text] [Related]
38. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial.
Loehrer PJ; Johnson D; Elson P; Einhorn LH; Trump D
J Clin Oncol; 1995 Feb; 13(2):470-6. PubMed ID: 7531223
[TBL] [Abstract][Full Text] [Related]
39. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience.
Saxman SB; Finch D; Gonin R; Einhorn LH
J Clin Oncol; 1998 Feb; 16(2):702-6. PubMed ID: 9469360
[TBL] [Abstract][Full Text] [Related]
40. A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study.
Fizazi K; Delva R; Caty A; Chevreau C; Kerbrat P; Rolland F; Priou F; Geoffrois L; Rixe O; Beuzeboc P; Malhaire JP; Culine S; Aubelle MS; Laplanche A
Eur Urol; 2014 Feb; 65(2):381-6. PubMed ID: 24094847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
